The metabolic dysfunction-associated steatohepatitis (MASH) drug resmetirom exhibits broad nuclear receptor activity with minimal functional impact

Key Points

• Resmetirom shows broad nuclear receptor activity with minimal functional impact, supporting its potential in treatment.
• The significant finding indicates effective nuclear receptor modulation, improving aspects of metabolic dysfunction.
• Assessment of resmetirom's impact on nuclear receptor activity demonstrates its relevance in steatohepatitis management.
• This analysis highlights the need for further studies to explore resmetirom's therapeutic benefits in metabolic disorders.